TG Therapeutics Investigational Trial Site

Urbana, Illinois 61801

1 studies enrolling now · 5 studies all time

What they study most

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Sclerosis, Relapsing Multiple Sclerosis

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 — Stopped early
• Ublituximab + Ibrutinib in Select B-cell Malignancies — Completed
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) — Completed